Skip to main content
Log in

Trialogue

Managing hyperglycaemia in internal medicine: instructions for use

  • CONSENSUS PAPER
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

Abstract

Hyperglycaemic patients admitted to hospital have worse clinical outcomes with higher operational costs than normoglycaemic patients. Identifying, defining and treating hyperglycaemia promptly and appropriately is essential during hospitalisation; adequate ‘continuity of care’ must be assured after discharge. This requires a multidisciplinary clinical collaboration between the internist and the diabetes team, which plays a central role in the treatment course and should be involved soon after patient admission to the hospital. This document aims to establish guidelines and recommendations for good clinical practice in managing hyperglycaemic internal medicine patients, with or without previous diagnosis of diabetes. The Associazione Medici Diabetologi (AMD), Federazione delle Associazioni dei Dirigenti Ospedalieri Internisti (FADOI) and Società Italiana di Diabetologia (SID) have decided to publish a document useful for internists in the management of hospitalised patients with hyperglycaemia. The Trialogue project, coordinated by a Board of Scientific Experts from the three scientific societies, was initiated for this purpose. A questionnaire consisting of 16 multiple choice questions on the management of hyperglycaemia in hospital was answered by 660 physicians from over 250 Internal Medicine units distributed throughout Italy. Analysis of responses has yielded an overview of routine clinical practice and provided a wealth of ideas to better identify critical points in the treatment of hospitalised patients with hyperglycaemia. These recommendations were developed with the aim of providing mutually agreed practical guidance (instructions for use) that can be readily applied by healthcare professionals in routine clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

Acknowledgments

We thank Concetta Baldo, Stefania Frasson, Maria Grazia Riceputi, Antonella Valerio and Irene Zaratti of the FADOI Study Centre for the collection and processing of data. The Trialogue project has been realised with an unconditional contribution from Sanofi.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Roberto Trevisan.

Additional information

Communicated by Guido Pozza.

The document was published in Italian: Il Giornale di AMD (2012;15:93-100), Italian Journal of Medicine (2012; 6:123-132), Il Diabete (2012; 24).

Appendix: Participants in the Trialogue project

Appendix: Participants in the Trialogue project

AMD

Coordinators: Carlo Bruno Giorda (Turin), Sandro Gentile

(Naples)

Expert Panel: Raffaella Fresa (Cava de’ Tirreni, Salerno), Valeria Manicardi (Montecchio E., Reggio Emilia), Maria Chantal Ponziani (Novara)

FADOI

Coordinators: Carlo Nozzoli (Florence), Mauro Campanini

(Novara)

Expert Panel: Giampietro Beltramello (Bassano del Grappa,

Vicenza), Giuseppe Campagna (Latina), Audenzio D’Angelo

(Palermo), Luigi Magnani (Voghera), Domenico Panuccio (Bologna), Giuseppe Seghieri (Pistoia)

SID

Coordinators: Gabriele Riccardi (Naples), Stefano Del Prato

(Pisa)

Expert Panel: Alberto Bruno (Turin), Domenico Mannino

(Reggio Calabria), Roberto Trevisan (Bergamo)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beltramello, G., Manicardi, V. & Trevisan, R. Trialogue. Acta Diabetol 50, 465–473 (2013). https://doi.org/10.1007/s00592-013-0462-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-013-0462-1

Keywords

Navigation